FranceFrance

GM maize ban to continue

05.03.2012

Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The latest scientific studies would show that the use of the GM crops “pose significant risks for the environment,” the ministry said in a statement. The study in question is an expert’s report on Syngenta’s Bt11 maize that was published by the European Food Safety Authority (EFSA) in December 2011. This line produces the same Bacillus thuringiensis (Bt) toxin as MON810. In the study, EFSA’s GMO Panel gave the green light for the EU cultivation of Bt11, but highlighted a number of concerns about the possible negative impacts on insect populations, including butterflies and moths. As with other Bt-plants, the study also mentions the potential risk of sub­-populations of targeted pest insects developing resistance, which would require adequate resistance management. In terms of biological efficacy, the panel reaches the conclusion that Bt11 and MON810 can be considered equivalent. The French Environment Ministry is now basing its arguments on that analogy, saying the report raises new doubts about the environmental risks of MON810. France will re-impose a temporary ban on the cultivation of GM maize if the Commission does not impose an EU-wide moratorium before the planting season begins, government officials said. In January, Monsanto announced it is not planning to sell MON810 in France anyway, as the political climate in the country is ill-disposed to accept GMOs.

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/gm-maize-ban-to-continue.html

Product of the week

Products

Events

All Events

Current issue

All issues